Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, has entered into a definitive agreement with Gilead Sciences, Inc. (GILD) for the acquisition of its polymerase theta ATPase inhibitor, RP-3467.
Under the terms of the agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment and an additional $5 million milestone payment tied to technology transfer activities.
RP-3467 is a highly potent small-molecule inhibitor of polymerase theta (Pol?), a synthetic lethality target associated with BRCA mutations and other genomic alterations. The drug is currently being evaluated in the POLAR Phase 1 trial, which is testing RP-3467 alone or in combination with olaparib in patients with advanced ovarian, breast, prostate, and pancreatic cancers.
This transaction marks Repare's third portfolio deal in 2025, and the most significant to date. The upfront payment strengthens Repare's cash balance and is expected to impact its pending acquisition by Xeno Therapeutics. Based on revised estimates, Repare shareholders are expected to receive approximately US$2.20 per share at the closing of the Xeno transaction.
Repare's CEO Steve Forte commented, "We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class polymerase theta ATPase inhibitor."
The acquisition underscores Gilead's continued push into oncology and synthetic lethality approaches, while providing Repare with near-term liquidity ahead of its broader strategic transaction.
RPTX has traded between $0.89 and $2.30 over the past year. The stock is currently trading in the pre-market at $2.62, up 20.73%, touching a new 52-week high.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.